Drug Profile
Research programme: nanoliposomal docetaxel - TRACON
Latest Information Update: 11 Sep 2014
Price :
$50
*
At a glance
- Originator TRACON Pharmaceuticals
- Class
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 18 Jun 2007 Preclinical trials in Cancer in USA (unspecified route)